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ptimal Antiplatelet
herapy During Percutaneous
oronary Interventions Includes
lycoprotein IIb/IIIa Inhibitors
ust Eliminate the Infusion*
htisham Mahmud, MD, FACC,
nand Prasad, MD
a Jolla, California
he benefits of glycoprotein (GP) IIb/IIIa inhibitors are
ell established for patients with an acute coronary syn-
rome (ACS) treated with an early invasive strategy, espe-
ially in the presence of high-risk features (troponin posi-
ivity, ST-segment depression on presentation, recurrent
schemia, or high TIMI [Thrombolysis In Myocardial
nfarction] risk score) (1). These benefits exists even in the
resence of thienopyridine pre-treatment (2). In contrast,
esults of studies with and without thienopyridine pre-
reatment suggest that the utility of GP IIb/IIIa inhibitors
uring elective percutaneous coronary intervention (PCI) is
imited (3–5).
See page 837
Regardless of the specific moiety studied (the chimeric
ntibody abciximab or the small molecules tirofiban or
ptifibatide), optimal efficacy of GP IIb/IIIa inhibitors
equires a high degree of platelet inhibition during the PCI
6,7). The clinical benefits from potent inhibition of platelet
ggregation, specifically the reduction of myocardial infarc-
ion (MI), death, and urgent target vessel revascularization,
re also accompanied by an increased risk of major and
inor bleeding (2–5,8,9). Although a higher risk of bleed-
ng with GP IIb/IIIa inhibitors was observed in all of the
linical trials that established indications for these agents,
leeding was never included as a primary end point in these
tudies because reduction of ischemic events was thought to
e of far greater significance.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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12 h for abciximab and 12 to 18 h for tirofiban/eptifibatide)
fter successful PCI was also a part of the clinical trial
esigns used to obtain approval of these agents for clinical
se. Although an early study with abciximab and PCI
balloon angioplasty only) suggested that a bolus-only ap-
roach with abciximab led to a higher ischemic event rate,
his study was performed in the pre-stent era and has never
een replicated (10). No subsequent study has adequately
upported the need for a prolonged infusion of a GP
Ib/IIIa inhibitor after an uncomplicated and successful
CI, especially with routine stenting and thienopyridine
re-treatment.
The REPLACE-2 (Randomized Evaluation in PCI Link-
ng Angiomax to Reduced Clinical Events-2) trial was a major
ractice-modifying study in interventional cardiology and led
o the widespread adoption of bivalirudin, as opposed to
nfractionated heparin with GP IIb/IIIa inhibitor, for non-
mergent PCI (11). In this study, 6,010 subjects (86% pre-
reated with a thienopyridine) undergoing nonemergent PCI
ere randomly assigned to bivalirudin (with 7% bailout GP
Ib/IIIa inhibitor) versus unfractionated heparin with routine
P IIb/IIIa inhibitor. The study showed noninferiority for
schemic end points of bivalirudin with provisional GP IIb/IIIa
lockade, as compared with heparin plus planned GP IIb/IIIa
nhibitor, and also demonstrated lower rates of major and
inor bleeding with bivalirudin. Importantly, the absence of a
ajor bleed during the index PCI translated to lower 1-year
ortality (12). Therefore, this study highlighted the impor-
ance of including major bleeding as an important clinical end
oint, and introduced the concept of a quadruple end point
death, MI, repeat revascularization, and major bleeding) to
stablish efficacy and safety of antiplatelet/anticoagulant
herapy (13).
In this issue of the Journal, Fung et al. (14) present the
esults of a well-executed study showing that in the absence
f certain pre-procedural high-risk features (unprotected
eft main, ST-segment elevation, MI 48 h, visible throm-
us at initial angiography), and intraprocedural complica-
ions (type B or worse coronary dissection, distal emboliza-
ion, side branch loss, hemodynamic collapse, prolonged
schemia, unsuccessful femoral arteriotomy closure), the
ptimal use of the GP IIb/IIIa inhibitor eptifibatide during
CI may be as a bolus dose and truncated infusion (2 h).
he investigators randomly allocated 624 subjects with
table angina or ACS who had undergone successful coro-
ary stenting with eptifibatide to a standard 18-h infusion
ersus a truncated 2-h infusion of the GP IIb/IIIa
nhibitor. The 2-h duration of infusion was chosen to allow
he antiplatelet effect of a 600 mg bolus dose of clopidogrel
n the absence of thienopyridine pre-treatment. This epti-
batide regimen provided the combined benefit of high
nhibition of platelet aggregation during the PCI procedure
nd, with a brief infusion, the potential for a lower risk of
leeding. The incidence of periprocedural myonecrosis as
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March 10, 2009:846–8 GP IIb/IIIa Inhibitors for PCI-Bolus Onlyefined by troponin elevation 0.26 g/l was similar
etween the 2 groups (28.3% vs. 30.1%, 18 h vs. 2 h,
espectively; p  0.012 for noninferiority), with similar
0-day rates of death, MI, and target vessel revasculariza-
ion (p  ns). The incidence of non–Q-wave MI at 30 days
as also similar (4.5% vs. 4.8%, 18 h vs. 2 h, respectively;
 1.0). However, the major bleed rate (REPLACE-2
efinition) was higher in the 18-h infusion group (4.2% vs.
.0%, 18 h vs. 2 h, respectively; p  0.02). A major
imitation of this study is the use of periprocedural troponin
levation as a primary end point, which is not known to be
n adverse long-term prognostic factor after PCI. The study
s otherwise not powered to adequately address the tradi-
ional clinical ischemic end points. However, importantly,
his study shows that a brief infusion of eptifibatide is not
ssociated with a higher risk of ischemic events after PCI
nd results in a lower rate of major bleeding.
Other studies have shown that the evaluation of clinical
nd procedural angiographic parameters can be used to
redict the likelihood of a periprocedural MI after PCI
15,16). In the absence of pre-procedural high-risk charac-
eristics and intraprocedural complications, a prolonged
nfusion of a GP IIb/IIIa inhibitor or bivalirudin is likely of
imited value in reducing the risk of ischemic events, and yet
ikely to increase the risk of bleeding. Bertrand et al. (17)
sed the transradial approach with 1,005 patients undergo-
ng PCI and demonstrated noninferiority of abciximab
olus only compared with bolus plus 12-h infusion for both
schemic and bleeding end points. Marmur et al. (18) have
eported their retrospective experience with both the epti-
batide and tirofiban bolus-only approach during PCI,
btaining acceptably low ischemic and bleeding event rates
ith both agents.
The optimal pharmacological antiplatelet regimen to
alance ischemic efficacy with the risk of periprocedural
leeding remains in flux. Promising agents in investigational
se include the oral P2Y12 antagonists prasugrel and
ZD6140, which lead to higher platelet inhibition com-
ared with clopidogrel, and the nonthienopyridine agent
angrelor, a potent intravenous, rapidly acting, and revers-
ble (platelet recovery time 20 to 50 min) P2Y12 receptor
ntagonist (19). The oral thrombin receptor antagonist
RA-SCH 530348 also results in potent inhibition of
latelet aggregation and is in clinical trials. The exact role of
hese agents and their impact on GP IIb/IIIa inhibitor
dministration and choice of antithrombin (heparin versus
ivalirudin) therapy during PCI remains uncertain.
The results of the BRIEF-PCI (Brief Infusion of Intra-
enous Eptifibatide Following Successful Percutaneous
oronary Intervention) study by Fung et al. (14) provide
airly convincing evidence that a prolonged infusion of the
P IIb/IIIa inhibitor eptifibatide is likely to be of limited
alue after a successful and uncomplicated PCI. With the
esults of this study and currently available data (17,18), the
P IIb/IIIa inhibitor eptifibatide given as a bolus withruncated infusion until the end of the PCI procedureecomes an attractive alternative to bivalirudin for PCI
atients. Owing to variability in the platelet reactivity
esponse to clopidogrel, even with thienopyridine pre-
reatment, a substantial proportion of patients do not have
ptimal platelet inhibition during PCI (20). Because isch-
mic complications of PCI are predominantly a platelet-
ediated phenomenon, and pre-procedural clinical or an-
iographic criteria are imperfect in predicting the likelihood
f a periprocedural MI, the bolus dose of eptifibatide can
rovide maximal degree of platelet inhibition during all PCI
rocedures regardless of thienopyridine pre-treatment or
lopidogrel hyporesponsiveness. Furthermore, as the inci-
ence of a periprocedural MI after a successful and uncom-
licated PCI is extremely low, the increased bleeding risk of
prolonged infusion of GP IIb/IIIa inhibitor could be
voided by eliminating the infusion after the end of the PCI
rocedure.
eprint requests and correspondence: Dr. Ehtisham Mahmud,
ardiovascular Catheterization Laboratories, UCSD Medical
enter, 200 West Arbor Drive, San Diego, California 92103-
784. E-mail: emahmud@ucsd.edu.
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